HIV antiretroviral resistance occurs when changes in the virus reduce the effectiveness of medicines used to control infection. These changes, often caused by genetic mutations, can affect how different antiretroviral drugs work. Understanding resistance mechanisms helps explain why some treatments become less effective over time and why regular monitoring is important.
HIV antiretroviral resistance is an important consideration in long-term treatment management. Understanding how resistance develops, which viral components are involved, and how different drug classes are affected provides insight into treatment effectiveness and the importance of consistent monitoring.
HIV has a high mutation rate because its reverse transcriptase enzyme frequently makes copying errors when converting viral RNA into DNA. Although many mutations have little effect, some changes allow the virus to survive exposure to specific antiretroviral medications.
When treatment does not fully suppress viral replication, resistant viral variants may gain an advantage and multiply. This process is known as drug selection pressure. Over time, resistant strains can become more prominent within the viral population.
Several biological and treatment-related factors contribute to resistance development:
Genetic mutations: Changes in viral genetic material can modify proteins targeted by antiretroviral drugs.
Incomplete viral suppression: When medication does not adequately control viral replication, opportunities for resistance to develop may increase.
Drug selection pressure: Antiretroviral medicines can favor viral variants that carry resistance-associated mutations.
Treatment interruptions: Repeated interruptions or inconsistent medication use can contribute to viral rebound and resistance, depending on the drug regimen.
Previous treatment exposure: Earlier treatment experiences may influence which resistance mutations are present.
Resistance can be transmitted between individuals when a person acquires an HIV strain that already carries resistance-associated mutations. This is called transmitted drug resistance.
Different antiretroviral drug classes target specific viral proteins or processes. Resistance develops when mutations change these targets or allow HIV to overcome the effects of medication.
Understanding these mechanisms helps explain why resistance to one medication does not necessarily mean resistance to every antiretroviral drug.
Reverse transcriptase inhibitors interfere with the enzyme responsible for converting HIV RNA into DNA. Two major categories are nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Resistance-associated mutations can change the enzyme's structure, reducing medication effectiveness. Some mutations also allow the enzyme to remove certain NRTI compounds from the growing viral DNA chain.
Examples include:
M184V mutation: Associated with high-level resistance to lamivudine and emtricitabine.
K65R mutation: Can reduce susceptibility to several NRTIs.
K103N mutation: Associated with resistance to certain NNRTIs, including efavirenz and nevirapine.
Thymidine analogue mutations: A group of mutations that can reduce susceptibility to certain NRTIs.
Protease inhibitors prevent HIV protease from processing viral proteins into functional components needed for viral maturation. Mutations in the protease gene can change the enzyme's structure and reduce the ability of medications to bind effectively.
Integrase inhibitors target the integrase enzyme, which allows HIV DNA to become part of the host cell's genetic material. Resistance can develop through mutations in the integrase gene.
Important considerations include:
Protease mutations: Changes in the protease enzyme can reduce susceptibility to individual drugs or multiple medications within the same class.
Integrase mutations: Changes such as Q148H, N155H, and Y143-associated mutations can affect susceptibility to certain integrase inhibitors.
Cross-resistance: Some mutations can reduce the effectiveness of multiple drugs within the same antiretroviral class.
Drug-specific resistance: Certain mutations affect particular medications more strongly than others.
Laboratory testing helps identify whether HIV carries genetic changes associated with reduced susceptibility to antiretroviral medications. Genotypic resistance testing examines viral genetic material to identify known resistance-associated mutations.
Phenotypic resistance testing evaluates how effectively different antiretroviral medications inhibit viral replication in laboratory conditions.
These tests provide important information in clinical management:
Identify mutations associated with resistance to specific drug classes.
Help assess possible cross-resistance between medications.
Support treatment selection when virological failure occurs.
Identify transmitted drug resistance before or during initial treatment evaluation.
Provide information about the potential effectiveness of alternative antiretroviral medicines.
Resistance testing results are interpreted alongside viral load measurements, previous treatment history, and other clinical information. This helps healthcare professionals understand the possible causes of incomplete viral suppression and evaluate appropriate treatment options.